viewCytoDyn Inc.

CytoDyn hopes to convince FDA & federal gov't to grant approvals with coronavirus patient data

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan and diagnostic advisor Dr Bruce Pattersen tell Proactive that recent blood work shows that seven severe coronavirus patients being treated with its drug leronlimab in New York City have shown a significant improvement after seven days in several important biologic markers.

What's more, the duo say three patients in Southern California improved dramatically after being given leronlimab. Pourhassan says he hopes to convince the FDA and federal government to grant approvals with its most recent coronavirus patient data.

Quick facts: CytoDyn Inc.

Price: 3.7599 USD

Market: OTCQB
Market Cap: $1.95 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...



CytoDyn reveals latest mild-to-moderate coronavirus patient data in Phase 2...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan says its drug leronlimab showed early clinical improvement in mild-to-moderate coronavirus patients in a recently completed Phase 2 trial. Pourhassan says in patients with a Total Clinical Symptom Score of 4 or more, with higher scores indicating...

2 days, 6 hours ago

2 min read